New Two-Pronged drug tested in fight against advanced lung cancer
NCT ID NCT04900363
Summary
This study tested an experimental drug called AK112 in 108 people with advanced non-small cell lung cancer. AK112 is a single antibody designed to attack cancer in two ways at once: by blocking a protein that helps tumors hide from the immune system and by cutting off their blood supply. The main goals were to see if the drug could shrink tumors and how safe it was for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
Conditions
Explore the condition pages connected to this study.